Mitsubishi Tanabe Dispatched Diabetes Specialists For Launch Of DPP-4 Inhibitor Teneria
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharmaceuticals announced Aug. 31 it plans to deploy 1,600 general sales reps and 50 reps specializing in diabetes to provide information on the new DPP-4 inhibitor Teneria it will launch Sept. 10.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.